<DOC>
	<DOC>NCT02888197</DOC>
	<brief_summary>Non-interventional extension study to investigate VVC recurrence and candida colonization following the P2 acute VVC study</brief_summary>
	<brief_title>Non-Interventional Extension to Investigate Recurrence of Vulvovaginal Candidiasis and Candida Colonization</brief_title>
	<detailed_description>Following completion of the Phase 2, multicenter, randomized, active-controlled study of the safety and tolerability of two formulations of CD101 compared to fluconazole for the treatment of moderate to severe episodes of acute vulvovaginal candidiasis (NCT07299432), subjects without a recurrence of VVC will be followed up to an additional 90 days +/- 14 days to assess candida colonization and recurrence of VVC.</detailed_description>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Candidiasis</mesh_term>
	<mesh_term>Vaginitis</mesh_term>
	<mesh_term>Candidiasis, Vulvovaginal</mesh_term>
	<criteria>Enrollment in and completed the primary study through the Day 28 visit. Received at least one dose of study drug in the primary study Able to give written informed consent prior to completion of the primary study Received systemic or topical vaginal nonstudy antifungal therapy at any time during the primary study Diagnosed with bacterial vaginosis, trichomonas, gonorrhea, chlamydia, or active herpes at any point during the primary study The Principal Investigator considers that the subject should not participate in the study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>